LEWISVILLE, TX – med fusion, a Roche Molecular Center of Excellence and a leader in advanced laboratory diagnostics, is proud to announce the launch of their plasma based EGFR Liquid Biopsy service. The service utilizes Roche’s FDA-approved cobas® EGFR Mutation Test v2 to identify 42 mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutations, to help physicians select eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).


The EGFR Liquid Biopsy service augments med fusion’s existing decision support tools for physicians treating NSCLC patients, LungSEQ® and 50SEQ® Plus FISH. Using a simple blood draw, it provides a non-invasive alternative for EGFR mutation testing in NSCLC patients when tissue biopsies cannot be obtained or the available specimen is scarce. EGFR mutation status helps physicians determine which treatment options, e.g. EGFR TKIs, are likely to benefit patients with metastatic NSCLC.


med fusion’s ultimate goal is to improve patient care by providing responsible precision medicine solutions,” said Jon Hart, med fusion’s Chief Executive Officer. “Expanding our menu to include the EGFR Liquid Biopsy test helps us accomplish our goal by providing physicians with a reliable, non-invasive test to determine EGFR mutation status and related treatment options for their NSCLC patients when tissue biopsies are not available.


We’re honored that med fusion is using Roche’s test as the basis for their EGFR Liquid Biopsy service,” said Jack Phillips, President and CEO of Roche Diagnostics Corporation. “This is a service that will benefit their network of physicians and the lung cancer patients they serve, and we are proud to be part of it.


About med fusion
med fusion, an integrated Roche Molecular Center of Excellence and clinical trials service organization, delivers support to healthcare providers and biotech/pharmaceutical companies to consistently meet the needs of patients. An industry leader in advanced laboratory diagnostics and support, our full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of responsible precision medicine by specializing in: Oncology, Women’s Health, Urology, and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers its specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.


Media Contact
Lori Brisbin
Chief Commercial Officer
med fusion